From 25% in early January
Proven prevention effect… Up to 80% reduction in clinical infection probability
The dosing of COVID-19 antibody treatments in the United States is accelerating.
According to CNN on the 21st (local time), the dosage rate (dosage ratio to the amount of supply) of the COVID-19 antibody treatment, which remained at the level of 25% at the beginning of the year, is estimated to have reached 39% as of last week. Eli Lilly announced last week that the information was shared with the public-private military joint Corona 19 response program’Operation Warp Speed’.
The U.S. government started supplying it across the U.S. after approval for the emergency use of the Corona 19 antibody treatment developed by Eli Lily and Regeneron in November last year.
WCHS, a local broadcaster in West Virginia, reported that more than 400 patients have been given antibody treatments since last month from Mountain Health Network, a medical institution in Cabell County.
Dr. Hoit Burdick, the hospital’s chief medical officer, said, “No one has been admitted to the hospital after administration of the antibody treatment, and no patients have worsened symptoms.” It should be administered weekly.” “Until everyone is vaccinated, monoclonal antibodies are an important factor in stopping Corona 19 early.”
In Texas, media reports from a local medical facility (Joe Arrington Cancer Center and Infusion Services) that more than 600 patients have received antibody treatments since November last year. “Almost all patients who received antibody treatment have fully recovered from Corona 19,” said Shelley Bix, the head of the medical facility. “The monoclonal antibody attaches to human receptors and plays a role in protecting against Corona 19.”
Research results on the anti-corona19 effect of antibody treatments have also been published. Bloomberg News reported that the administration of balmranibimab, a Corona 19 antibody treatment developed by Eli Lilly, to nursing home residents reduced the risk of Corona 19 infection by up to 80%.
This is the result of a study of about 1,000 people, including 299 nursing home residents and 666 nursing home staff. Eight weeks after the administration of the antibody therapy, the overall probability of symptoms in those receiving the antibody therapy or placebo decreased by 57%. Those who received balmranibimab had an 80% lower chance of infection. There were 4 deaths in the placebo group during the study period, but none of those receiving antibody therapy.
Celltrion in Korea(313,500 +0.48%)It is developing Rekironaju, a treatment for the COVID-19 antibody. As a result of global phase 2 clinical trials, the probability of developing a severe patient compared to the placebo group based on moderately ill patients 50 years of age or older with pneumonia was reduced by 68% and the recovery period was shortened by 5-6 days or more.
Currently, it has applied for conditional approval from the Ministry of Food and Drug Safety based on the results of phase 2 clinical trials. It is undergoing global phase 3 clinical trials in 10 foreign countries including Europe.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution